lovastatin has been researched along with Idiopathic Parkinson Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CH; Chao, YT; Chen, YC; Cheng, MF; Huang, TL; Lin, CH; Tai, CH; Wu, RM; Yen, RF | 1 |
| Cao, LP; Chen, ML; Chien, CT; Farrer, MJ; Lai, TT; Lin, CH; Lin, HI; Wu, RM | 1 |
| Bornefall, P; Eriksson, I; Giraldo, AM; Nath, S; Öllinger, K | 1 |
| Adame, A; Kelly, J; Koob, AO; Mante, M; Masliah, E; Paulsson, JF; Rockenstein, E; Ubhi, K | 1 |
| Kazis, LE; Lee, A; Lee, TA; Li, NC; Wang, SW; Wolozin, B | 1 |
| Kuhn, W; Müller, T; Pöhlau, D; Przuntek, H | 1 |
1 trial(s) available for lovastatin and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
A Double-Blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson's Disease.
Topics: Double-Blind Method; Follow-Up Studies; Humans; Lovastatin; Mental Status and Dementia Tests; Parkinson Disease | 2021 |
5 other study(ies) available for lovastatin and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
Topics: Animals; Animals, Genetically Modified; Dopaminergic Neurons; Drosophila melanogaster; Glycogen Synthase Kinase 3 beta; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Lovastatin; Mice; Motor Neurons; Mutation; Nerve Degeneration; Neurites; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-akt; Serine Endopeptidases; Signal Transduction | 2016 |
Impact of high cholesterol in a Parkinson's disease model: Prevention of lysosomal leakage versus stimulation of α-synuclein aggregation.
Topics: alpha-Synuclein; Anticholesteremic Agents; Cell Line, Tumor; Cell Survival; Cholesterol; Humans; Lovastatin; Lysosomes; Parkinson Disease; Reactive Oxygen Species | 2017 |
Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Brain; Cholesterol; Dendrites; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lewy Body Disease; Lovastatin; Mice; Mice, Transgenic; Microtubule-Associated Proteins; Neurons; Oxidation-Reduction; Parkinson Disease; Platelet-Derived Growth Factor; Thy-1 Antigens | 2010 |
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Databases as Topic; Dementia; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Parkinson Disease; Proportional Hazards Models; Pyrroles; Simvastatin; United States; Veterans | 2007 |
Parkinsonism unmasked by lovastatin.
Topics: Aged; Female; Humans; Lovastatin; Male; Middle Aged; Parkinson Disease | 1995 |